COVID-19 Device EUA Exit Reshapes US Procurement

What the FDA action changes

The FDA’s action closes an emergency regulatory route used to make COVID-19 tests, respirators, personal protective equipment and other medical devices available before completion of the agency’s standard premarket review. An EUA is not approval, clearance or licensure. Once an authorization ends, the product does not automatically become conventionally authorized, even if clinicians and laboratories have used it for years.

The practical consequence is product-specific. An EUA may have been revoked, allowed to expire under a transition arrangement or replaced by a conventional marketing authorization. Some products originally supplied under an EUA later obtained FDA clearance, approval or another lawful marketing status; those products may remain available under that status and its labeling. Others cannot continue to be commercially distributed merely because units remain in a warehouse or clinical department.

Health systems should not treat “COVID-19 device” as a single inventory category. The FDA maintains separate authorization records and lists for diagnostic tests, personal protective equipment, ventilators and other devices. The controlling documents are the applicable EUA letter, any revocation notice, the FDA’s current authorization lists and, where relevant, a subsequent clearance or approval record.

The end of an EUA is also distinct from the end of the federal COVID-19 public health emergency. EUA authority arises under the Federal Food, Drug, and Cosmetic Act and can continue after a public health emergency declaration ends. Conversely, the FDA can revise or revoke individual authorizations while broader emergency authorities remain in place.

A product-by-product review is now necessary

Laboratories and procurement teams need a shared inventory that identifies the manufacturer, exact product name, model or catalog number, lot number, expiration date and current location. For tests, the record should also distinguish instruments, reagents, collection devices, software versions and control materials. A platform may have several assays with different regulatory statuses.

Each item should then be matched against the FDA’s current records. The review should answer four separate questions: Was the product marketed only under an EUA? Did it later receive conventional authorization? Does an FDA notice permit continued use of already-distributed units?

Are there conditions governing labeling, records, adverse-event reporting, return or disposal?

Hospitals should avoid assuming that remaining stock can be used until its printed expiration date. Shelf life and legal authorization are different issues. The applicable FDA notice may address whether products already distributed can remain in use and under what conditions. If the notice is silent or the product cannot be identified precisely, the matter should be escalated to regulatory, laboratory and supply-chain leadership rather than resolved by local custom.

A concise transition register can make these decisions auditable.

Implications for laboratories and clinical testing

Clinical laboratories should separate FDA marketing status from their obligations under the Clinical Laboratory Improvement Amendments. FDA authorization determines whether a test may be lawfully marketed under the relevant pathway. CLIA governs laboratory quality, personnel, performance specifications and testing practices. Compliance with one framework does not substitute for compliance with the other.

When replacing an EUA-only assay with a cleared or approved test, a laboratory still needs to complete the verification or validation required for its setting before reporting patient results. The scope depends on the test’s complexity, intended use, specimen types, platform and whether the laboratory modifies the manufacturer’s instructions. Changes to specimen type, pooling, software or result interpretation can create additional regulatory and validation questions.

Laboratories should preserve EUA-era records according to applicable requirements and institutional retention policies. Useful records include validation and verification studies, lot acceptance data, quality-control results, proficiency testing, complaints, corrected reports and communications about software or labeling changes. Ending an authorization does not erase obligations associated with testing performed while it was in effect.

Clinical teams also need advance notice if the transition changes specimen collection, turnaround time, reporting language or access. Replacing a rapid near-patient assay with a centralized method, for example, may alter isolation, treatment or discharge workflows even when the tests serve a similar diagnostic purpose. Those operational effects should be assessed separately from analytic performance.

Respirators and other devices require separate checks

Respirators illustrate why EUA status should not be used as a proxy for overall suitability. During the pandemic, emergency pathways covered certain imported respirators, decontamination systems and other products that did not follow the usual route. A current National Institute for Occupational Safety and Health approval, where applicable, is separate from an FDA EUA and should be verified independently.

Procurement specifications should identify the required regulatory and occupational-safety status rather than merely requesting an “N95” or “COVID-approved” product. Teams should confirm the manufacturer, model, approval markings, intended clinical use and compatibility with the organization’s respiratory-protection program. Fit testing, training and infection-control policy remain necessary even when a respirator has the appropriate regulatory status.

The same principle applies to ventilator accessories, remote-monitoring products, barrier devices and sterilization or decontamination systems. A component may have been authorized only for a defined emergency use, with particular compatible devices or settings. Continued use should be based on current labeling and authorization, not on previous deployment during the pandemic.

What manufacturers and distributors must address

Manufacturers should determine whether each EUA product has a conventional FDA submission, an accepted transition plan or no continuing marketing pathway. The FDA’s transition guidance describes expectations for devices that were distributed under an EUA and for manufacturers seeking continued distribution after emergency authorization ends.

Key tasks include stopping distribution when no lawful pathway remains, updating labeling and promotional materials, communicating with customers, retaining required records and following applicable complaint and medical-device reporting duties. Manufacturers should also reconcile field inventory and clarify whether already-distributed devices may be used, returned, relabeled or disposed of.

A pending premarket submission should not be treated as an authorization unless the FDA has provided a specific transition policy allowing continued distribution. Health systems purchasing a product during the transition should request documentary evidence of current status rather than relying on a vendor’s statement that clearance is “in process.” Contracts may need provisions covering regulatory-status changes, replacement stock, recalls, software support and disposal costs.

Limits and unresolved questions

This is a regulatory transition, not a comparative clinical study. It provides no effect estimate, confidence interval or evidence that an EUA device is clinically inferior to a cleared or approved alternative. The change concerns the legal basis for marketing and use; product performance must be considered from each device’s supporting evidence, labeling and local quality data.

Consequences will vary by product and by the wording of individual FDA notices. Central FDA pages can also change as authorizations are revised or archived. Organizations therefore need dated records of the documents used for each decision and a process for checking subsequent updates.

Access effects remain uncertain. Switching assays or suppliers can increase costs, reduce near-patient capacity or create short-term shortages, particularly for smaller laboratories. Those risks support early procurement planning, but they do not create authority to continue purchasing or using a product after its lawful pathway has ended.

Questions clinicians ask

Can we keep using an EUA test already in stock?

Possibly, but the answer is product-specific. The laboratory should confirm the FDA’s current listing, the EUA letter and any revocation or transition notice. A printed expiration date alone does not establish permission to use the test after authorization ends, and local leaders should document the basis for continued use.

Does ending an EUA mean the device was unsafe or inaccurate?

No. Ending emergency authorization changes the product’s regulatory status and does not, by itself, establish a safety or performance defect. Clinicians should distinguish an administrative transition from a recall or safety communication and review the FDA’s product-specific notice, labeling and performance evidence before drawing clinical conclusions.

Must a laboratory validate the replacement assay again?

A laboratory generally must complete the verification or validation required for the replacement method and its intended use under CLIA. The needed work depends on test complexity, specimen types, platform and local modifications; prior experience with an EUA assay does not automatically establish performance for a different cleared or approved test.

Are N95 respirators automatically affected by the EUA change?

Not uniformly. Some respirators and related systems used emergency pathways, while others hold separate NIOSH approvals or conventional FDA status. Procurement and occupational-health teams should verify the exact manufacturer and model, required approval markings, intended use and fit-testing requirements rather than relying on a generic N95 description.

References

1. Emergency Use Authorization — US Food and Drug Administration, 2026
2. COVID-19 Emergency Use Authorizations for Medical Devices — US Food and Drug Administration, 2026
3. Transition Plan for Medical Devices Issued Emergency Use Authorizations Related to Coronavirus Disease 2019 — US Food and Drug Administration, 2023
4. Clinical Laboratory Improvement Amendments — Centers for Medicare & Medicaid Services, 2026